A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Oric Pharmaceuticals, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 12,832 shares of ORIC stock, worth $105,864. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,832
Holding current value
$105,864
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$7.52 - $11.9 $96,496 - $152,700
12,832 New
12,832 $131,000
Q1 2023

May 09, 2023

BUY
$4.26 - $6.75 $6,773 - $10,732
1,590 Added 3.82%
43,225 $246,000
Q4 2022

Feb 10, 2023

SELL
$2.41 - $5.89 $22,109 - $54,034
-9,174 Reduced 18.06%
41,635 $245,000
Q3 2022

Nov 10, 2022

BUY
$3.15 - $5.24 $93,699 - $155,869
29,746 Added 141.22%
50,809 $163,000
Q2 2022

Aug 05, 2022

BUY
$2.7 - $7.07 $56,870 - $148,915
21,063 New
21,063 $94,000

Others Institutions Holding ORIC

About Oric Pharmaceuticals, Inc.


  • Ticker ORIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,576,700
  • Market Cap $327M
  • Description
  • ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...
More about ORIC
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.